Frank Yocca - 14 Mar 2022 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Scientific Officer
Signature
/s/ Javier Rodriguez, as Attorney-in-Fact for Frank Yocca, Ph.D.
Issuer symbol
BTAI
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4
Filing time
16 Mar 2022, 16:15:43 UTC
Next filing
24 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Award $0 +8,337 $0.000000 8,337 14 Mar 2022 Common Stock 8,337 Direct F1, F2
transaction BTAI Stock Option (Right to Buy) Award $0 +33,350 $0.000000 33,350 14 Mar 2022 Common Stock 33,350 $15.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.